Abstract
The treatment of GBM tumor recurrence is generally a hopeless challenge, since recurred tumor is resistant to the most common therapeutic efforts. Some partial results can be achieved by targeting local disease control, in view of the fact that 95% of recurrences occur locally. We present results concerning three pilot studies, all performed in recurrent GBM patients who underwent second surgery and have been treated systemically with temozolomide and locally through an Ommaya reservoire according to the following schedules: a) in 20 rGBM, 4 mg novantrone was delivered day 1,5 every 30 days; in 26 rGBM, 4 mg novantrone was delivered every 20 days in association with locoregional radioimmunotherapy (RIT); in 12 rGBM pegylated liposomal doxorubicin 4 mg was delivered day 1,5,10,15,20 with 20 days interval. Results seem very promising since there is an extension of disease free and survival, both of more than 50% if results are evaluated in relation with the most frequent data of the literature.
| Original language | English |
|---|---|
| Pages (from-to) | 123-127 |
| Number of pages | 5 |
| Journal | Journal of Experimental and Clinical Cancer Research |
| Volume | 22 |
| Issue number | 4 SUPPL. |
| Publication status | Published - Dec 2003 |
Fingerprint
Keywords
- Glioblastoma recurrence
- Local chemotherapy
- Locoregional radioimmunotherapy
- Mitoxantrone
- Pegylated doxorubicin
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
New Approach in Delivering Chemotherapy : Locoregional Treatment for Recurrent Glioblastoma (rGBM). / Boiardi, Amerigo; Eoli, M.; Salmaggi, A.; Lamperti, E.; Botturi, A.; Broggi, G.; Bartolomei, M.; Silvani, A.
In: Journal of Experimental and Clinical Cancer Research, Vol. 22, No. 4 SUPPL., 12.2003, p. 123-127.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - New Approach in Delivering Chemotherapy
T2 - Locoregional Treatment for Recurrent Glioblastoma (rGBM)
AU - Boiardi, Amerigo
AU - Eoli, M.
AU - Salmaggi, A.
AU - Lamperti, E.
AU - Botturi, A.
AU - Broggi, G.
AU - Bartolomei, M.
AU - Silvani, A.
PY - 2003/12
Y1 - 2003/12
N2 - The treatment of GBM tumor recurrence is generally a hopeless challenge, since recurred tumor is resistant to the most common therapeutic efforts. Some partial results can be achieved by targeting local disease control, in view of the fact that 95% of recurrences occur locally. We present results concerning three pilot studies, all performed in recurrent GBM patients who underwent second surgery and have been treated systemically with temozolomide and locally through an Ommaya reservoire according to the following schedules: a) in 20 rGBM, 4 mg novantrone was delivered day 1,5 every 30 days; in 26 rGBM, 4 mg novantrone was delivered every 20 days in association with locoregional radioimmunotherapy (RIT); in 12 rGBM pegylated liposomal doxorubicin 4 mg was delivered day 1,5,10,15,20 with 20 days interval. Results seem very promising since there is an extension of disease free and survival, both of more than 50% if results are evaluated in relation with the most frequent data of the literature.
AB - The treatment of GBM tumor recurrence is generally a hopeless challenge, since recurred tumor is resistant to the most common therapeutic efforts. Some partial results can be achieved by targeting local disease control, in view of the fact that 95% of recurrences occur locally. We present results concerning three pilot studies, all performed in recurrent GBM patients who underwent second surgery and have been treated systemically with temozolomide and locally through an Ommaya reservoire according to the following schedules: a) in 20 rGBM, 4 mg novantrone was delivered day 1,5 every 30 days; in 26 rGBM, 4 mg novantrone was delivered every 20 days in association with locoregional radioimmunotherapy (RIT); in 12 rGBM pegylated liposomal doxorubicin 4 mg was delivered day 1,5,10,15,20 with 20 days interval. Results seem very promising since there is an extension of disease free and survival, both of more than 50% if results are evaluated in relation with the most frequent data of the literature.
KW - Glioblastoma recurrence
KW - Local chemotherapy
KW - Locoregional radioimmunotherapy
KW - Mitoxantrone
KW - Pegylated doxorubicin
UR - http://www.scopus.com/inward/record.url?scp=1842478671&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1842478671&partnerID=8YFLogxK
M3 - Article
C2 - 16767918
AN - SCOPUS:1842478671
VL - 22
SP - 123
EP - 127
JO - Journal of Experimental and Clinical Cancer Research
JF - Journal of Experimental and Clinical Cancer Research
SN - 0392-9078
IS - 4 SUPPL.
ER -